Genmab A (GMAB) EBT Margin Growth (1y) (2019 - 2026)
Powered by 
Analysis
Genmab A (GMAB) EBT Margin Growth (1y) (2019 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 208.48 Bn | 194.49 Bn | 7.24 Bn | 1,045.00 |
| 2 | Gilead Sciences | 186.29 Bn | 183.02 Bn | 6.22 Bn | -16,571.00 |
| 3 | Vertex Pharmaceuticals | 128.79 Bn | 120.93 Bn | 2.84 Bn | -153.00 |
| 4 | Regeneron Pharmaceuticals | 80.66 Bn | 72.67 Bn | 3.93 Bn | -571.00 |
| 5 | Moderna | 61.46 Bn | 56.32 Bn | 52.00 Mn | 4,709.00 |
| 6 | Argenx Se | 61.28 Bn | 56.10 Bn | 1.37 Bn | 553.00 |
| 7 | Alnylam Pharmaceuticals | 32.04 Bn | 28.73 Bn | 992.69 Mn | 1,911.00 |
| 8 | Biogen | 31.84 Bn | 30.56 Bn | 1.96 Bn | -2,328.00 |
| 9 | Roivant Sciences | 28.74 Bn | 29.43 Bn | 1.16 Mn | -801,907.00 |
| 10 | Genmab A | 2.23 Bn | 728.64 Mn | 1.07 Bn | -1,513.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -1,513.00 |
| Mar 31, 2026 | -2,587.00 |
| Sep 30, 2025 | 636.00 |
| Jun 30, 2025 | 44.00 |
| Mar 31, 2025 | -717.00 |
| Sep 30, 2024 | -2,015.00 |
| Jun 30, 2022 | 651.00 |
| Dec 31, 2021 | -5,800.00 |
| Sep 30, 2021 | 1,177.00 |
| Jun 30, 2021 | -719.00 |
| Dec 31, 2020 | 1,219.00 |
| Sep 30, 2020 | -2,833.00 |
| Jun 30, 2020 | 6,506.00 |
| Dec 31, 2019 | 2,869.00 |